OFIX Stock - Orthofix Medical Inc.
Unlock GoAI Insights for OFIX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $799.49M | $746.64M | $460.71M | $464.48M | $406.56M |
| Gross Profit | $545.88M | $486.27M | $337.17M | $349.56M | $304.67M |
| Gross Margin | 68.3% | 65.1% | 73.2% | 75.3% | 74.9% |
| Operating Income | $-84,619,000 | $-139,110,000 | $-13,268,000 | $-8,315,000 | $-6,266,000 |
| Net Income | $-125,997,000 | $-151,395,000 | $-19,749,000 | $-38,379,000 | $2.52M |
| Net Margin | -15.8% | -20.3% | -4.3% | -8.3% | 0.6% |
| EPS | $-3.30 | $-4.12 | $-0.98 | $-1.95 | $0.13 |
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 28th 2025 | Stifel | Resumed | Buy | $22 |
| January 22nd 2025 | Canaccord Genuity | Initiation | Buy | $24 |
| November 8th 2024 | Stifel | Upgrade | Buy | $24← $18 |
| May 8th 2024 | ROTH MKM | Upgrade | Buy | $20← $15 |
| October 20th 2023 | ROTH MKM | Initiation | Neutral | $12 |
| September 12th 2023 | BTIG Research | Downgrade | Neutral | - |
| September 12th 2023 | Stifel | Downgrade | Hold | - |
| July 19th 2023 | BTIG Research | Resumed | Buy | $27 |
Earnings History & Surprises
OFIXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $0.44 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.12 | $0.20 | +66.7% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.04 | $0.13 | +225.0% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.17 | $-0.08 | +52.9% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $0.06 | $0.02 | -66.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.14 | $0.07 | +150.0% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.13 | $0.05 | +138.5% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.32 | $-0.46 | -43.8% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.22 | $0.07 | +131.8% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.67 | $0.02 | +103.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.20 | $-0.10 | +50.0% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.37 | $0.19 | +151.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.12 | $0.13 | +11.4% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $0.07 | $0.08 | +14.3% | ✓ BEAT |
Q2 2022 | May 6, 2022 | $0.18 | $-0.10 | -155.6% | ✗ MISS |
Q1 2022 | Feb 25, 2022 | $0.13 | $0.27 | +107.7% | ✓ BEAT |
Q4 2021 | Nov 5, 2021 | $0.13 | $0.10 | -23.1% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $0.16 | $0.32 | +100.0% | ✓ BEAT |
Latest News
Barrington Research Maintains Outperform on Orthofix Medical, Raises Price Target to $18
📈 PositiveOrthofix Medical Narrows FY2025 Sales Guidance from $808.000M-$816.000M to $810.000M-$814.000M vs $813.559M Est
➖ NeutralOrthofix Medical Q3 Adj. EPS $0.20, Sales $205.600M Beat $200.006M Estimate
📈 PositiveStifel Reinstates Buy on Orthofix Medical, Announces $22 Price Target
📈 PositiveBarrington Research Maintains Outperform on Orthofix Medical, Maintains $17 Price Target
📈 PositiveFrequently Asked Questions about OFIX
What is OFIX's current stock price?
What is the analyst price target for OFIX?
What sector is Orthofix Medical Inc. in?
What is OFIX's market cap?
Does OFIX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OFIX for comparison